The tumor suppressor BRCA1 is mutated in a high percentage of familial breast and ovarian cancer, but our understanding of its mechanisms of action remains incomplete. We report here that glucose-regulated protein (GRP)-78, a critical regulator of the unfolded protein response (UPR), is a novel downstream target of BRCA1. We showed that overexpression of wild-type BRCA1 suppressed the expression of GRP78, whereas expression of mutant BRCA1 gene or targeted inhibition of endogenous BRCA1 using small-interfering RNA (siR-NA) enhanced GRP78 expression. Knockdown of BRCA1 also led to induction of other components of UPR, such as GRP94 and CHOP. Consistent with a role of BRCA1 knockdown in mediating cell survival, forced expression of GRP78 stimulated cell proliferation and prevented apoptosis, including that induced by endoplasmic reticulum stress and chemotherapy, in ovarian OVCAR-3 and breast MCF-7 cancer cells. Overexpression of wild-type BRCA1 could increase the apoptosis of GRP78-overexpressing cells. Conversely, knockdown GRP78 by siRNA sensitized ovarian and breast cancer cells to apoptosis. This effect was reduced when the expression of BRCA1 was simultaneously knockdown by siRNA, indicating that BRCA1 also negatively regulates GRP78-mediated cell survival and resistance to apoptosis.
Introduction
BRCA1 is the most important cancer susceptibility gene found in breast and ovarian cancer. Germline mutation of BRCA1 is responsible for 30-40% of familial breast cancer cases. Familial ovarian cancer comprises at least 10% of cases (Welcsh and King, 2001 ). In addition, BRCA1 expression is often decreased or absent in sporadic breast and ovarian cancers, suggesting that BRCA1 may also play a role in nonhereditary tumors (Wilson et al., 1999; Zheng et al., 2000) . The biological function of the BRCA1 protein appears to be complex as this protein has been implicated in the regulation of a variety of cellular processes including maintenance of genome integrity, DNA damage repair, cell cycle control and apoptosis (Welcsh and King, 2001 ). However, its molecular function remains unclear. A better understanding of the downstream targets of BRCA1 is necessary so that the most appropriate therapeutic targets may be identified.
Recently, we used a proteomic approach to identify previously unknown BRCA1 target proteins by comparing the protein profiles of ovarian surface epithelial (OSE) cells from women with a history of familial ovarian and/or breast cancer (FH-OSE), i.e., at least two first-degree relatives with such cancer and/or testing positive for BRCA1 mutations, to those without such history (He et al., 2005) . This led to the discovery that the unfolded protein response (UPR) regulator glucoseregulated protein (GRP)-78 was upregulated in FH-OSE. The association between increased GRP78 and malignancy has previously been implicated in various ovarian and breast cancer cell lines and tumors, suggesting a pathological role for GRP78 in ovarian and breast cancers (Fernandez et al., 2000; Shin et al., 2003; Lee, 2007) .
GRP78, a 78-kDa protein also referred to as BiP, is a major stress-inducible chaperone localized to the endoplasmic reticulum (ER). It facilitates proper folding of proteins and assists in their assembly and transport out of the cell. Importantly, GRP78 is a key component of the UPR required to alleviate ER stress, maintain ER function and protect cells against death (Lee, 2005) .
Results and discussion
Loss of BRCA1 function induces GRP78 gene expression To evaluate the ability of BRCA1 to regulate GRP78, we first transfected OVCAR-3 cells with the wild-type BRCA1 construct. Overexpression of wild-type BRCA1 suppressed the expression of GRP78 (Figure 1a) .
Conversely, we asked whether expression of dominantnegative BRCA1 truncation mutant (D1815-1863) that represents a common BRCA1 mutation found in BRCA1-associated ovarian and breast cancer families could enhance expression of GRP78. The ectopic expression of BRCA1 (D1815-1863) was indicated by a truncated protein of 210 kDa using anti-BRCA1 (Figure 1b, left panel) . This was also confirmed by real-time PCR analysis using a sense primer designed against sequence from the pcDNA3.1 vector that was absent in the endogenous transcript and an antisense primer located in the transfected BRCA1 gene (data not shown). We found that expression of the mutant BRCA1 (D1815-1863) caused a 2.3-fold increase in GRP78 protein and mRNA expression compared with the control vector (Figure 1b) . The expression of b-actin as an internal control was not changed. As an alternative approach, we utilized a BRCA1-specific small-interfering RNA (siRNA) approach. This may mimic the underexpression of BRCA1 commonly observed in ovarian and breast cancers despite the underlying mechanisms (Welcsh and King, 2001) . Western blot and real-time (RT)-PCR analysis confirmed inhibition of endogenous BRCA1 after transfection with the BRCA1-specific siRNA compared with the control nonspecific siRNA (Figure 1c ). The BRCA1 siRNA had no effect on BRCA2 (data not shown). siRNA-mediated inhibition of endogenous BRCA1 significantly (2.4-fold) increased GRP78 protein and mRNA compared to controls (Figure 1c ). This effect was not observed for b-actin. Knockdown of BRCA1 also stimulated the induction of other components of UPR, such as GRP94 and CHOP (Figure 1c ), indicating that loss of BRCA1 activates the UPR stress response. Furthermore, overexpression of wild-type BRCA1 suppressed GRP78 promoter activity, whereas BRCA1 (D1815-1863) and BRCA1 siRNA stimulated the GRP78 promoter, a standard indicator for the trigger of the UPR (Lee, 2005) (Figure 1d ). In addition, there was an inverse correlation between BRCA1 and GRP78 expression in cell lines (Figure 1e ). CaOV-3 and MDA-MB-231 cells expressed low levels of BRCA1 demonstrating higher expression of GRP78 than others (Figure 1e ). Together, these results suggest a negative regulatory role of BRCA1 on GRP78.
Stable overexpression of GRP78 in ovarian and breast cancer cells To study the function of GRP78 in ovarian and breast cancer, we transfected empty vector or His-tagged GRP78 expression constructs (Zeng et al., 2004) into OVCAR-3 and MCF-7 that had the lowest endogenous level of GRP78 protein of the cell lines tested. Two independently isolated G418-resistant clones of each cell line were isolated. In each case, parental and empty vector controls had little GRP78. Transfected clones expressed high levels of GRP78 as determined by western blot with anti-GRP78 or with anti-His for the presence of the binding epitope (Figure 2a ). Whole-cell imaging revealed prominent staining in transfected cells and was apparent in the perinuclear region, consistent with ER localization of GRP78 (Figure 2b ). Nonspecific staining was not detected in cells in which the primary antibody had been omitted or substituted by mouse immunoglobulin G (IgG; data not shown). The known ER stress-inducing agents tunicamycin (inhibitor of protein glycosylation) and 2-deoxy-D-glucose (hypoglycemia-inducing agent) induced a dose-dependent increase on GRP78 expression (Figure 2c ). GRP78 protein levels expressed in the stable cell lines were comparable to cells treated with tunicamycin and 2-deoxy-D-glucose (Figure 2c ), indicating the expression was in the range that is attained under experimental ER stress.
BRCA1 counters GRP78 during stress-induced apoptosis Overexpression of GRP78 substantially enhanced apoptosis resistance in both cancer cell lines (Supplementary Figure 1) . It has been reported that BRCA1 regulates apoptosis of breast and ovarian cancer cells in response to serum deprivation and a number of other apoptotic stimuli (Thangaraju et al., 2000) . To evaluate whether GRP78 may mediate the protective function of BRCA1 on cellular apoptosis, GRP78-overexpressing cells were exposed to multiple stress conditions, including tunicamycin, 2-deoxy-D-glucose and paclitaxel (the first-line chemotherapy in ovarian and breast cancer), and apoptosis was examined by Hoechst (data not shown), 4,6-diamidino-2-phenylindole (DAPI) as well as TdT-mediated dUTP nick end labelling (TUNEL) (Figure 3a) . Clearly, overexpression of GRP78 significantly decreased the amount of apoptosis induced by tunicamycin (OVCAR-3, B50% inhibition; MCF-7, B69% inhibition), 2-deoxy-D-glucose (OVCAR-3, B44.7% inhibition; MCF-7, B75% inhibition) and upon treatment with paclitaxel (OVCAR-3, B57% inhibition; MCF-7, B65% inhibition) than in parent and empty vector controls (Figure 3a) . Furthermore, overexpression of wild-type BRCA1 reversed the GRP78-mediated cell survival in GRP78-overexpressing OVCAR-3 and MCF-7 cells (Figure 3b ), supporting the potential involvement of BRCA1 in regulating GRP78 action.
To test further whether BRCA1 acts through GRP78 and contributes to resistance to apoptotic stimuli, we used siRNA to knockdown GRP78 and BRCA1, either alone or in combination. The expression of GRP78 and BRCA1 protein was substantially reduced by their specific siRNA as compared with control siRNA (Figure 4a ). Consistent with the above results in Figure 1c , the siRNA against BRCA1 efficiently increased expression of GRP78, GRP94 and CHOP (Figure 4a ). Knockdown of GRP78 by siRNA enhanced tunicamycin-, 2-deoxy-D-glucose-and paclitaxel-induced increase in apoptosis as compared with cells transfected with control siRNA, whereas knockdown of BRCA1 decreased cellular apoptosis (Figure 4b) . Furthermore, knockdown of GRP78 significantly reduced the decreased apoptosis mediated by knockdown of BRCA1. The reduction was more than GRP78 knockdown alone (Po0.05). These results suggest a . Endogenous BRCA1 (wt) encoded a protein approximately 220 kDa. BRCA1 (D1815-1863) was a truncated protein of 210 kDa. (c) Cells were transfected with 10 nM of BRCA1 small-interfering RNA (siRNA) SMARTpool (catalog no. 003461) or a control nonspecific (NS) siRNA (Dharmacon, Lafayette, CO, USA) using SilentFect (Bio-Rad, Hercules, CA, USA), in accordance with the manufacturer's protocol. At 48 h after transfection, BRCA1 and GRP78 expressions were analysed by western blotting (left panel) with the anti-BRCA1 (556443) polyclonal antibody (PharMingen, San Diego, CA, USA) or anti-GRP78 monoclonal antibody (BD Biosciences, San Jose, CA, USA). For real-time PCR analysis, total RNA was prepared using TRIzol and reversed transcribed using SuperScript reverse transcriptase (Invitrogen, Carlsbad, CA, USA). Real-time PCR was performed using the iCycler iQ Real-Time detection system and the IQ SYBR Green Supermix (Bio-Rad) with GRP78 primers: forward, 5 0 -CTGGGTACATTTGATCTGACTGG-3 0 ; reverse: 5 0 -GCATCCTGGTGGCTTTCCAGCCA-3 0 (right panel). b-Actin was included as an internal control. siRNA-mediated changes of GRP94 and GRP78 were analysed by anti-KDEL monoclonal antibody (StressGen, Victoria, Canada) and CHOP (C/EBP homologous protein) by anti-CHOP/GADD153 monoclonal antibody (Santa Cruz, Santa Cruz, CA, USA). The signal intensity was determined by densitometry, and the levels of BRCA1, GRP78, GRP94 and CHOP were normalized against that of b-actin. (d) Wt BRCA1-, BRCA1 (D1815-1863)-or siRNA-expressed cells were transiently transfected with 1 mg of reporter construct of the GRP78 promoter (-169/Luc) (Lee, 2005) . All cells were co-transfected with pSV-b-galactosidase (Promega, Madison, WI, USA). After 24 h, the cells were lysed and luciferase activities were determined. Luciferase values were normalized for transfection efficiency by b-galactosidase activity. The relative luciferase activities were calculated relative to pcDNA3.1 or NS siRNA, which as arbitrarily assigned a value of '1'. (e) Total cell lysates from ovarian cancer cell lines CaOV-3, SKOV-3 and OVCAR-3 (left panel), and breast cancer cell lines MCF-7, MDA-MB-231 and T47D (right panel) were analysed by western blot for the presence of BRCA1 and GRP78 proteins. All experiments were repeated three times, and data are shown as mean ± s.d. ) and MCF-7 (right panel) cells were treated with 1 mg/ml tunicamycin, 5 mM 2-deoxy-D-glucose (Sigma), and 100 mM paclitaxel (Merck, Darmstadt, Germany) for 48 h. Apoptosis was measured by DAPI (4,6-diamidino-2-phenylindole) and TdT-mediated dUTP nick end labelling (TUNEL) staining and visualized by fluorescent microscopy. DAPI-stained cells exhibiting condensed, pyknotic or fragmented nuclei were representative of apoptotic cells. TUNEL assay was performed using an in situ cell death detection kit (Roche, Indianapolis, IN, USA) per the manufacturer's instructions. Omission of the enzyme was used as a negative control. Data points shown represent the mean percentage of apoptotic cells counted in five fields in replicate wells from three independent experiments (lower panel). (b) Stable GRP78-expressing OVCAR-3 and MCF-7 cells transfected with wild-type (Wt) BRCA1 were treated with tunicamycin, 2-deoxy-D-glucose, and paclitaxel for 48 h. Apoptosis was measured by TUNEL staining, and results are mean of three independent experiments. Bars represent s.d. *Po0.05 versus parental controls.
BRCA1 modulates UPR signaling
BHY Yeung et al critical role of BRCA1 in the negative regulation of GRP78 and show that BRCA1 inactivation inhibits stress-induced apoptosis in breast and ovarian cancer cells, at least in part, through induction of GRP78. Similar results were also obtained when these experiments were done in CaOV-3, SKOV-3 and MDA-MB-231 ovarian and breast cancer cell lines, indicating that these findings were not merely due to a cell line-specific phenotype (data not shown).
The most interesting aspect of this work was the finding that, in addition to its well-established role in transcriptional regulation, BRCA1 may be an important modulator of protein homeostasis, and this may represent a new antitumoral mechanism of BRCA1. Evidence is emerging for a role of BRCA1 in the ubiquitination pathway through its interaction with a deubiquitinating enzyme, BAP1, and components such as BARD1 that contribute to its ubiquitin ligase activity (Jensen et al., 1998; Mallery et al., 2002) . Along this line, it is tempting to speculate that malfolded proteins may accumulate in the cytosol upon mutation or loss of BRCA1, which may negatively impact ER stressinduced protein degradation in the cancer microenvironment. GRP78 is known to function as a major ER chaperone. It offers protection against malfolded protein accumulation and suppresses apoptosis. Furthermore, BRCA1 has been reported to upregulate chaperone activity of HSP27 (Ma et al., 2003) . Our results also suggest a possible role for BRCA1 beyond DNA repair in the maintenance of genome integrity (Gowen et al., 1998; Moynahan et al., 1999) . GRP78 represents an important pro-survival component of UPR (Lee, 2005) . In yeast, UPR has been shown to be required for correct chromosome duplication and segregation (Lee et al., 2003) that are essential for the maintenance of intact genomes. There are reports that BRCA1-deficient mice or cultured cells displayed various chromosome abnormalities, and that this effect was mediated through the ability of BRCA1 to stabilize topoisomerase IIa (Xu et al., 2001; Lou et al., 2005) . Interestingly, topoisomerase IIa has also been identified as a GRP78 target gene and is downregulated by GRP78 (Reddy et al., 2003) . The nature and extent to which GRP78 functions in the BRCA1-mediated chromosome segregation is unknown but raises an intriguing question for future investigation.
In conclusion, we have identified a previously unknown function of BRCA1 in mediating UPR that correlated with GRP78 induction. These results not only expand the spectrum of biological properties of BRCA1, but also suggest the potential role of GRP78 as an additional therapeutic target, which, if inhibited, may allow BRCA1-deficient cells to become susceptible to environmental stress and drug response.
